Compare OLP & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | BBNX |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.2M | 493.1M |
| IPO Year | 1995 | N/A |
| Metric | OLP | BBNX |
|---|---|---|
| Price | $22.62 | $10.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $26.75 | $23.80 |
| AVG Volume (30 Days) | 52.1K | ★ 1.1M |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $82,740,000.00 | N/A |
| Revenue This Year | $11.98 | $34.90 |
| Revenue Next Year | $3.71 | $34.63 |
| P/E Ratio | $19.80 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $8.80 |
| 52 Week High | $25.90 | $32.71 |
| Indicator | OLP | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 41.33 |
| Support Level | $22.11 | $9.36 |
| Resistance Level | $23.42 | $11.92 |
| Average True Range (ATR) | 0.43 | 1.10 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 18.10 | 27.68 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.